Ginsenoside Rg-1 Protects Retinal Pigment Epithelium (RPE) Cells from Cobalt Chloride (CoCl₂) and Hypoxia Assaults

Ke-ran Li¹,², Zhi-qing Zhang³,⁴, Jin Yao¹, Yu-xia Zhao¹, Jing Duan³, Cong Cao²*, Qin Jiang¹*

¹ Department of Eye, the Affiliated Eye Hospital of Nanjing Medical University, Nanjing, Jiangsu, China, ² Institute of Neuroscience, Soochow University, Suzhou, Jiangsu, China, ³ The Center for Safety Evaluation of Drugs, Academic Institute of Pharmaceutical Science, China Pharmaceutical University, Nanjing, Jiangsu, China

Abstract

Severe retinal ischemia causes persistent visual impairments in eye diseases. Retinal pigment epithelium (RPE) cells are located near the choroidal capillaries, and are easily affected by ischemic or hypoxia. Ginsenoside Rg-1 has shown significant neuroprotective effects. This study was performed to test the cytoprotective effect of ginsenoside Rg-1 in RPE cells against hypoxia and cobalt chloride (CoCl₂) assaults, and to understand the underlying mechanisms. We found that Rg-1 pre-administration significantly inhibited CoCl₂- and hypoxia-induced RPE cell death and apoptosis. Reactive oxygen species (ROS)-dependent p38 and c-Jun NH2-terminal kinases (JNK) MAPK activation was required for CoCl₂-induced RPE cell death, and Rg-1 pre-treatment significantly inhibited ROS production and following p38/JNK activation. Further, CoCl₂ suppressed pro-survival mTOR complex 1 (mTORC1) activation in RPE cells through activating of AMP-activated protein kinase (AMPK), while Rg-1 restored mTORC1 activity through inhibiting AMPK activation. CoCl₂-induced AMPK activation was also dependent on ROS production, and anti-oxidant N-acetylcysteine (NAC) prevented AMPK activation and RPE cell death by CoCl₂. Our results indicated that Rg-1 could be further investigated as a novel cell-protective agent for retinal ischemia.

Introduction

In the pathology of central retinal vein occlusion (CRVO), age-related macular degeneration (AMD), diabetic retinopathy (DR) and retinopathy of prematurity (ROP), persistent retinal ischemia causes severe visual impairments, which will lead to blindness if not handled appropriately [1]. An interruption in blood supply to the retina will cause tissue ischemia, which leads to hypoxia and a rapid failure of energy production, and subsequent cell apoptosis or necrosis [1]. Several animal and cell models have been utilized to study retinal ischemia. Meanwhile, an increasing number of agents have been tested to interrupt the ischemic-hypoxia cascade, and to slow down or even reverse the retinal ischemia progression [2].

Ginseng is a well-known Chinese traditional medicine, and has shown significant anti-oxidative and pro-cell survival abilities [3]. It can also regulate intracellular calcium homeostasis in treating diabetes and cardiovascular disease [3,4,5]. It is safe and nontoxic to both animals and human even at high doses. Ginsenosides are the pharmacologically active components of ginseng. Among nearly 40 different ginsenosides isolated from ginseng, Ginsenoside Rg-1 is known as the major active component responsible for many pharmaceutical actions of ginseng [6,7,8]. Recent studies have shown that Rg-1 possesses significant neurotrophic and neuroprotective effects against stresses including hydrogen peroxide [9], β-amyloid [10,11,12], glutamate [6,13,14], 1-methyl-4-phenylpyridinium (MPP⁺) [15] and rotenone [16]. In vitro studies also demonstrated that Rg-1 is neuron protective in rat models of Parkinson’s disease (PD) [17,18,19], Alzheimer’s disease (AD) [20,21] and hypoxic-ischemic injuries [22]. In addition, Rg-1’s anti-inflammatory activities have also been shown by many groups. Rg-1 inhibits immune cells activation and subsequent release of pro-inflammatory cytokines, through preventing the activation of transcriptional factors NF-KB and MAPK [23,24,25]. Thus, ginsenoside Rg-1 is an ideal cell-protective candidate.

The retinal pigment epithelium (RPE) is the pigmented cell layer just outside the neurosensory retina that nourishes retinal visual cells, and is firmly attached to the underlying choroid and overlying retinal visual cells [26]. The RPE cells are located close to the choroidal capillaries, and are easily to be affected in an ischemic or hypoxia condition [27]. Considering that RPE cells are also neuron origin, in the current study, we studied the potential protective effect of Rg-1 against cobalt chloride (CoCl₂), chemical hypoxia) and hypoxia assaults in cultured RPE cell, and to investigate the underlying mechanisms.
Results

Rg-1 suppresses CoCl2-induced RPE cell death

Cell viability results in Figure 1A showed that Rg-1 by itself showed no cytotoxicity against RPE cells even at a high dose. As a matter of fact, it slightly increased RPE cell survival. CoCl2 stimulation at different concentrations (0, 200, 400, 600 and 800 μM, 24 hrs) caused significantly RPE cell viability reduction (cell death). The effect of CoCl2 was dose-dependent. 600 μM CoCl2 caused an approximate 50% reduction in RPE cell viability, and this concentration was set to induce RPE cell damage in the subsequent experiments (Figure 1B). As shown in Figure 1C, pretreatment with Rg-1 at concentrations of 50, 125 and 250 μM significantly inhibited CoCl2-induced reduction of cell viability, 25 μM of Rg-1 pre-administration also slightly suppressed RPE cell death by CoCl2, but the difference was not significant (Figure 1C). Cell morphological changes were consistent with the protective effect of Rg-1 against CoCl2 in RPE cells (Figure 1D).

Rg-1 inhibits CoCl2-induced apoptosis of RPE cells

The above results have shown that Rg-1 inhibits CoCl2-induced RPE cell damage. Next, we tested whether such an effect by Rg-1 was due to apoptosis prevention. The annexin V flow cytometry analysis was used to test the apoptosis of RPE cells. As shown in Figure 2A and B, Rg-1 pretreatment (25–125 μM) significantly inhibited RPE apoptosis by CoCl2 (600 μM). Note that Rg-1’s anti-apoptosis effect was dose-dependent (Figure 1B). Rg-1’s inhibitory role on cell apoptosis was further confirmed by TUNEL staining (Figure 2C and D) and caspase-3 activity assay (Figure 2E). Exposure to CoCl2 (600 μM) yielded 13.92% TUNEL-positive RPE cells (Figure 2C), and Rg-1 pretreatment (125 μM) significantly decreased the number of TUNEL-positive cells to 4.57% (Figure 2C and D). All the measurements indicated that the protective effect of Rg-1 against CoCl2 might be due to apoptosis inhibition.

Rg-1 inhibits CoCl2-induced ROS production and MAPK activation in RPE cells

Activation of the p38 and JNK MAPK pathway is strongly associated with cell apoptosis of many stresses. In our settings, we first examined the role of CoCl2 on p38 and JNK activation in RPE cells. Western blot results in Figure 3A demonstrated that CoCl2 (600 μM) administration induced significant p38 and JNK activation in RPE cells. Meanwhile, SB-239063, the p38 inhibitor and the JNK inhibitor SP-600125 suppressed CoCl2 (600 μM)-induced RPE cell death (Figure 3B) and apoptosis (Figure 3C), suggesting that p38/JNK1/2 activation was required for CoCl2-induced RPE cell damage. SB-239063 led to a stronger rescue effect than SP-600125 (Figure 3B and C), indicating that p38 activation might be more important than JNK activation in mediating CoCl2-induced RPE cytotoxicity. Importantly, as shown in Figure 3A, Rg-1 pre-administration (125 μM, 2 hrs pretreatment) almost blocked CoCl2-induced JNK and p38 activation in RPE cells, suggesting that the protective role of Rg-1 against CoCl2 might be associated with JNK/p38 inhibition. Further, we also examined ROS accumulation in CoCl2-treated RPE cells, and results showed that Rg-1 inhibited intracellular cellular ROS production by CoCl2 (Figure 3D and E). The fact that anti-oxidant NAC inhibited CoCl2-induced JNK/p38 activation (Figure 3G) and RPE cell death (Figure 3F) suggested that ROS is required for MAPK activation and cytotoxicity by CoCl2.
Activation of Akt and mammalian target of rapamycin complex 1 (mTORC1) signaling plays important roles in cell survival and apoptosis resistance. We then tested this pathway in CoCl2-treated RPE cells. Western blot results in Figure 4A showed that in RPE cells CoCl2 administration activated Akt while inhibiting mTORC1 (Figure 4A). Note that Akt activation was reflected by increased expression of phospho (p)-Akt (Ser 473), while p-S6 and p-4E-BP1 downregulation confirmed mTORC1 inhibition in CoCl2 treated cells(Figure 4A). Meanwhile, RAD001 and rapamycin, two mTORC1 inhibitors, blocked S6 phosphorylation (Figure 4B), both inhibitors also reduced RPE cell viability.

Figure 2. Rg-1 inhibits CoCl2-induced apoptosis of RPE cells. ARPE-19 cells were pre-treated with indicated concentration of Rg-1 (25, 50 and 125 μM) for 2 hrs, followed by CoCl2 (600 μM) administration, cells were further cultured for 24 hrs, cell apoptosis was analyzed by annexin V assay (A) and TUNEL staining (C), data of three sets of independent experiments were quantified (B for annexin V, D for TUNEL). The activity of caspase-3 was also detected (E). Data were expressed as mean ± SD. *p<0.05. For C and D, Rg1’s concentration was 125 μM. doi:10.1371/journal.pone.0084171.g002

Inactivation of mTORC1 by CoCl2 and restoring by Rg-1

Figure 4A showed that in RPE cells CoCl2 administration activated Akt while inhibiting mTORC1. Note that Akt activation was reflected by increased expression of phospho (p)-Akt (Ser 473), while p-S6 and p-4E-BP1 downregulation confirmed mTORC1 inhibition in CoCl2 treated cells(Figure 4A). Meanwhile, RAD001 and rapamycin, two mTORC1 inhibitors, blocked S6 phosphorylation (Figure 4B), both inhibitors also reduced RPE cell viability.
Figure 3. Rg-1 inhibits CoCl₂-induced ROS production and MAPK activation in RPE cells. ARPE-19 cells were pre-treated with Rg-1 (125 μM) for 2 hrs, followed by CoCl₂ (600 μM) administration, cells were further cultured for indicated time points, phospho (p-) and total (t)-p38 and JNK1/2 were analyzed by Western blots (A). ARPE-19 cells were pre-treated with p38 inhibitor SB-239063 (10 μM) or SP-600125 (10 μM) for 1 hr, followed by CoCl₂ (600 μM) administration, and cell viability and apoptosis were analyzed by MTT assay (B) and annexin V flow cytometry (C) respectively 24 hrs after stimulation. Cellular ROS level was also tested (D and E). The numbers in D mean relative ROS-DCFDA signal readout. ARPE-19 cells were pre-treated with indicated anti-oxidant NAC for 2 hrs, followed by CoCl₂ (600 μM) administration, cells were further cultured, p38 and JNK1/2 activation (F) as well as cell viability (G) were shown. Western blot data were quantified as described. Data were expressed as mean±SD. *p<0.05, doi:10.1371/journal.pone.0084171.g003
(Figure 4C). Thus mTORC1 activation is required for RPE cell survival. Importantly, Rg-1 pre-administration restored mTORC1 activation in CoCl2-treated RPE cells (Figure 4A). These results indicated that rescue of mTORC1 signaling by Rg-1 could also be linked to its pro-survival effect against CoCl2. It should be noted that Rg-1 alone also enhanced Akt and mTORC1 activation in RPE cells (Figure 4A, star label), which might explain why we saw an increased cell survival by Rg-1 alone (Figure 1A).

AMPK activation by CoCl2 mediates mTORC1 inhibition, reversed by Rg-1

Above results showed that CoCl2 inhibited mTORC1 activation in RPE cells. The well-known inhibitory kinase of mTORC1 is AMP-activated protein kinase (AMPK). Activated AMPK inhibits mTORC1 through the following mechanisms: by phosphorylation and activation of TSC2 (tuberous sclerosis protein 2) [28], or by phosphorylation of Raptor (regulatory associated protein of mTOR) [29]. We then tested AMPK activation in CoCl2-treated RPE cells. Western blot results in Figure 5A showed that CoCl2 induced significantly AMPK activation (AMPK/ACC phosphorylation) in RPE cells. While Rg-1 pre-administration almost blocked AMPK activation by CoCl2. Significantly, CoCl2-induced mTORC1 inhibition was alleviated in stable RPE cells with AMPKα knockdown (Figure 5B), indicating that activation of AMPK by CoCl2 is required for mTORC1 inhibition in RPE cells, and Rg-1 restores mTORC1 activity probably through preventing AMPK activation. Notably, the anti-oxidant N-acetylcysteine (NAC) dose-dependently inhibited AMPK activation by CoCl2 (Figure 5C), which indicates that ROS might be the upstream signal for CoCl2-induced AMPK activation in RPE cells (see [30,31]), and Rg-1’s inhibitory effect on AMPK activation could be due to its ability on ROS scavenging (Figure 3D and E).

Hypoxia-induced cytotoxicity and cytoprotection by Rg-1 in hypoxic RPE cells

When RPE cells were cultured in an anaerobic chamber (hypoxia), cell death developed in a time-dependent manner, and cell viability OD reduced when hypoxia lasted (Figure 6A). The most significant cell death induced by hypoxia was observed after 8 hrs after anaerobic chamber incubation. Rg-1 ranging from 125–250 μM significantly protected ARPE-19 cells from hypoxia-induced damage, and cell viability was restored. 25 μM of Rg-1 had no obvious protective effect (Figure 6A). Meanwhile, cell apoptosis was tested by Histone-DNA ELISA assay. Hypoxia induced significant apoptosis in ARPE-19 cells, such an effect was largely inhibited by Rg-1 (125–250 μM) pre-incubation (Figure 6B).

Discussion

Retinal ischemia is a pathological feature shared by many eye diseases including central retinal vein occlusion (CRVO), branch retinal vein occlusion (BRVO), diabetic retinopathy (DR), and retinopathy of prematurity (ROP). Thus, these diseases are collectively referred as ischemic retinopathies [32]. At the cellular level, ischemic retinal injury consists of a self-reinforcing destruc-

Figure 4. Inactivation of mTORC1 by CoCl2 and restoring by Rg-1. ARPE-19 cells were pre-treated with Rg-1 (125 μM) for 2 hrs, followed by CoCl2 (600 μM) administration, cells were further cultured for indicated time points, phospho (p)- and total -Akt, S6 and 4E-BP1 were analyzed by Western blots (A). ARPE-19 cells were treated with RAD001 (200 nM) and rapamycin (400 nM), after 4 hrs, phospho (p)- and total (t)-Akt, S6 and p-Erk1/2 as well as tubulin were examined (B), cell viability was analyzed by MTT assay after 24 hrs (C). Western blot data were quantified as described. Data were expressed as mean ± SD. #p<0.05. doi:10.1371/journal.pone.0084171.g004
Ginsenoside Rg-1 Protects RPE Cells from Hypoxia

Figure 5. AMPK activation by CoCl₂ mediates mTORC1 inhibition, reversed by Rg-1. ARPE-19 cells were pre-treated with Rg-1 (125 μM) for 2 hrs, followed by CoCl₂ (600 μM) administration, cells were further cultured for indicated time points, phospho (p)- and total -AMPKα1 and ACC were tested by Western blots, β-actin was also shown (A). The scramble or AMPKα1/2 siRNA expressing stable ARPE-19 cells were stimulated with CoCl₂ (600 μM) for 6 hrs, p- and t-S6/4E-BP1, as well as AMPKα2 and Akt were tested (B). ARPE-19 cells were pre-treated with indicated concentration of NAC for 2 hrs, followed by CoCl₂ (600 μM) administration, AMPK activation and β-actin expression were shown (C). Western blot data were quantified as described.

doi:10.1371/journal.pone.0084171.g005

Figure 6. Hypoxia-induced cytotoxicity and cytoprotection of Rg-1 in hypoxic RPE Cells. ARPE-19 cells were pre-treated with Rg-1 (25, 125 and 250 μM) for 2 hrs, cells were further cultured in an anaerobic chamber for 4, 8 and 12 hrs, cell viability was then tested by MTT assay (A). ARPE-19 cells were pre-treated with Rg-1 (25, 125 and 250 μM) for 2 hrs, cells were further cultured in an anaerobic chamber for 12 hrs, Histone-DNA ELISA OD was shown (B). (C) The proposed signaling pathway of the present study: In cultured RPE cells, Rg-1 exerts a significant cytoprotective effect against damage caused by CoCl₂ or hypoxia. CoCl₂ induces ROS production and subsequent JNK/p38 MAPKs activation leading to RPE cell apoptosis, which are largely inhibited by Rg-1. CoCl₂ inhibits pro-survival mTORC1 activation (S6/4E-BP1 phosphorylation) through activation of AMPK signaling, while Rg-1 inhibits AMPK activation and restores mTORC1 activation. Rg-1 also enhances cytoprotective Akt activation in RPE cells. Note that the green arrow stands for “promotes” or “activates”, while the red bar stands for “inhibits”. *p<0.05 vs. the hypoxia group.

doi:10.1371/journal.pone.0084171.g006
potential role of Rg-1 on retina and retinal cells. In the current study, we demonstrated that Rg-1 exerted a significant protective role against CoCl2 and hypoxia-induced RPE cell damage, which was associated with changes of multiple signaling pathways (Figure 6C). ROS production [34] and subsequent MAPK activation were proposed as major signaling mechanisms mediating cell death by hypoxia [35,36,37], and we found that Rg-1 significantly inhibited CoCl2-induced ROS accumulation and JNK/p38 activation by CoCl2 (Figure 6C). Further, CoCl2 inhibited pro-survival mTORC1 activation in RPE cells, and activation of AMPK was involved in the process. Rg-1 restored mTORC1 activation probably by inhibiting AMPK activation in RPE cells (Figure 6C).

Recently, different groups including us [38] have demonstrated that AMPK is an important regulator for cell apoptosis [39,40,41,42,43,44]. This serine/threonine kinase is originally thought to act as a cellular energy sensor by stimulating ATP-consuming anabolic pathways and inhibiting ATP-consuming catabolic pathways [45,46]. We and others proved that sustained AMPK activation could also promote cell apoptosis by regulating its downstream signals, including JNK [47,48,49], p38 [50,51], p53 [52,53]. Meanwhile, AMPK inhibits mTORC1 activation [54,55,56]. Our recent study and others have discovered that UV and H2O2-induced RPE cell apoptosis was also associated with AMPK activation [31,38,57]. In the current study, we also observed a significant AMPK activation in CoCl2 treated RPE cells, and Rg-1 pre-treatment blocked AMPK activation by CoCl2. The fact that NAC inhibited AMPK activation by CoCl2 suggests that ROS might be responsible for AMPK activation by CoCl2, and Rg-1’s inhibition on AMPK might be due to its role as an ROS scavenger.

Interestingly, although CoCl2 inhibited mTORC1 activation in RPE cells, it simultaneously activated Akt. These results suggested that CoCl2-mediated mTORC1 inhibition was not dependent on its effect on Akt, rather Akt activation by CoCl2 could be a negative feedback effect after mTORC1 inhibition. [see in other studies [58]]. As a matter of fact, both RAD001 and rapamycin, two mTORC1 blockers, also activated Akt (Ser 473 phosphorylation) in RPE cells (Figure 4B). These results suggested that CoCl2 mediated mTORC1 inhibition was probably due to AMPK activation, but not Akt. In conclusion, we here demonstrated the significant cytoprotective ability of Rg-1 against hypoxia- and CoCl2-induced cytoxicity in RPE cells, such an effect by Rg-1 was associated with ROS-MAPK inhibition and AMPK/mTOR regulation in RPE cells. Our results indicated that Rg-1 could be further investigated as a novel cell-protective agent for retinal ischemia.

Materials and Methods

Cell culture
Human retinal pigment epithelial cells (ARPE-19 cell line), a gift from Dr. Fu Shang at Tufts University [59,60], were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM)/Nutrient Mixture F-12 (DMEM/F12, Gibco Life Technologies, Carlsbad, CA), supplemented with 10% fetal bovine serum (FBS) (Hyclone, Shanghai, China), penicillin/streptomycin (1:100, Sigma, St. Louis, MO), and 4 mM L-glutamine and 0.19% HEPES (Sigma), in a humidified incubator at 37°C and 5% CO2.

Reagents and chemicals
Ginsenoside Rg-1 (purity 99%) was purchased from Amresco (Solon, OH). Cobalt chloride (CoCl2) was supplied as a sterile ready-to-use 800 mM stock solution (Sigma, France). SP-600125 (the JNK inhibitor), SB-239063 (the p38 inhibitor), N-acetylcysteine (NAC), rapamycin and RAD001 were purchased from Calbiochem (Darmstadt, Germany). All phosphorylated kinase antibodies and their non-phosphorylated control antibodies were obtained from Cell Signaling Tech (Danvers, MA). Rabbit monoclonal antibodies against tubulin and β-actin were purchased from Sigma (St. Louis, MO).

Cell viability assay
RPE cell viability was measured by the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) method as described [38]. Briefly, RPE cells were collected and seeded in 96-well plate at a density of 2×10^3 cells/cm². Different seeding densities were optimized at the beginning of the experiments. After overnight incubation, cells were exposed to indicated reagents at 37°C. After treatment, 20 μl of MTT tetrazolium (Sigma, St. Louis, MO) salt dissolved in Hank’s balanced salt solution at a concentration of 5 mg/ml was added to each well. Twenty-four hrs later, the medium was aspirated carefully from each well, and 150 μl of DMSO (Sigma, St. Louis, MO) was added to dissolve formazan crystals, and the absorbance of each well was obtained using a plate reader at a test wavelength of 490 nm with a reference wavelength of 630 nm. Media-only treated cells served to indicate 100% cell viability, and the relative survival was defined as absorbance of treated wells divided by that of controls. For each treatment, 6-wells were included. All experiments were performed in triplicate.

TUNEL staining
As reported [38], RPE cell apoptosis was detected by the TUNEL (Terminal deoxynucleotidyl transferase dUTP nick end labeling) In Situ Cell Death Detection Kit (Roche Molecular Biochemicals, Indianapolis, IN, USA) according to the manufacturer’s instructions. RPE cells were also stained with 4’,6’-diamino-2-phenylindole (DAPI, blue fluorescence; Molecular Probes) to visualize the cell nuclei. RPE cell apoptosis was determined by TUNEL fluorescence intensity recorded by the confocal microscopy. All experiments were performed in triplicate.

Caspase-3 activity assay
After treatment, the caspase-3 activity of RPE cells was measured by a fluorometric caspase-3 activity assay kit (Kai-Ji, Nanjing, China) according the manufacturer’s instructions. Briefly, the RPE cells were collected and lysed using lysis buffer provided. The caspase-3 activity colorimetric assay is based on the hydrolysis of the peptide substrate acetyl-Asp-Glu-Val-Asp- p-nitroaniline (Ac-DEVD-pNA) by caspase-3, resulting in the release of the p-nitroaniline (pNA) moiety. pNA has a high absorbance at 405 nm, which was detected by the plate reader. Caspase-3 activity in treatment group was normalized to control group. All experiments were performed in triplicate.

Cell apoptosis detection by annexin V staining
RPE cell apoptosis was detected by the Annexin V Apoptosis Detection Kit (Beyotime, Shanghai, China) according to the manufacturer’s protocol. Briefly, after treatment, one million RPE cells were stained with propidium iodide (PI) solution (5mg/mL, Invitrogen, CA) and annexin V (1mg/mL, Invitrogen, CA) for 30 min in 37°C. Both early (annexin V+/PI-) and late (annexin V+/PI+) apoptotic cells were sorted by fluorescence-activated cell sorting (FACS) (Becton Dickinson FACICS Calibur). All experiments were performed in triplicate.
Apoptosis assay by enzyme-linked immunosorbent assay (ELISA)

As previously reported [61], the Cell Apoptosis Histone-DNA ELISA Detection Kit PLUS (Roche, Palo Alto, CA) was utilized to further test quantify cell apoptosis, according to the manufacturer’s protocol. Briefly, RPE cells were collected and seeded in 96-well plate at a density of 2 x 10^4 cells/cm². After treatment, the cytoplasmic histone/DNA fragments from RPE cells were extracted and bound to the immobilized anti-histone antibody (included in the kit). Subsequently, the peroxidase-conjugated anti-DNA antibody (included in the kit) was added for the detection of immobilized histone/DNA fragments. After addition of substrate for peroxidase, the spectrophotometric absorbance of the samples was determined using a plate reader at a test wavelength of 405 nm. All experiments were performed in triplicate.

Reactive oxygen species (ROS) assay

The ROS level was determined by carboxy-H2DCFDA staining assay, which is based on the fact that the nonpolar, nonionic H2-DCFDA crosses cell membranes and is hydrolyzed into non-fluorescent H2-DCF by intracellular esterase. In the presence of ROS, H2-DCF is rapidly oxidized to become highly fluorescent DCF. After treatment, ARPE-19 cells were incubated with 1 µM of carboxy-H2-DCFDA at 37°C for 30 min. Cells (1 x 10^6) were then resuspended in phosphate-buffered saline (PBS, pH 7.4) and sent to flow cytometry analysis (BD bioscience). The percent of fluorescence-positive cells was recorded on a spectrofluorometer using excitation and emission filters of 488 and 530 nm. All experiments were performed in triplicate.

Stable siRNA knockdown of AMPKα1/2

The lentiviral particles containing scramble or AMPKα1/2 shRNAs [62] were purchased from Santa Cruz Biotech (Santa Cruz, CA). Lentiviral shRNAs were added to the ARPE-19 cells for 36 hrs, and stable clones expressing corresponding shRNAs were selected by puromycin (1.0 µg/ml). Cell culture medium containing puromycin was renewed every 48 hrs, until resistant colonies can be identified (4–5 passages). The expression level of AMPKα1/2 and loading controls in stable cells were tested.

Western blot analysis and data quantification

After indicated treatment, aliquots of 30 µg of lysed proteins (lysed by 40 mM HEPES [pH 7.5], 120 mM NaCl, 1 mM EDTA, 10 mM pyrophosphate, 10 mM glycerophosphate, 50 mM NaF, 0.5 mM orthovanadate, EDTA-free protease inhibitors [Roche] and 1% Triton) from each sample were separated by 10% SDS polyacrylamide gel electrophoresis and transferred onto a poly-vinylidene difluoride (PVDF) membrane (Millipore, Bedford, MA). After blocking with 10% instant non-fat dry milk for 1 hr, membranes were incubated with specific antibodies overnight at 4°C followed by incubation with secondary antibodies for 45 minutes at room temperature. The Western blot results were visualized by ECL machine. The intensity of each blot was quantified using Image J software after normalization to corresponding loading controls, and their value was expressed as fold change vs. the band labeled with “1.00”. All experiments were performed in triplicate.

Hypoxia-Induced Cytotoxicity in RPE cells

4 x 10^5 ARPE-19 cells were seeded onto 96-well microplates in a final volume of 100 µl culture medium per well. Hypoxia-related cytotoxicity over time was investigated by placing the cells in an anaerobic chamber (<1% oxygen) for 4, 8, and 12 hrs. Part of wells were pretreated with indicated concentration of Rg-1, at the indicated time points, an MITT assay was performed. All experiments were performed in triplicate.

Statistical analysis

Individual culture dishes or wells were analyzed separately (no pooling of samples was used). In each experiment a minimum of three wells/dishes of each treatment were used. All the values in the figures are expressed as the means ± SD. Statistical significance was determined using one-way ANOVA followed by Scheffe’s f-test by using SPSS software (SPSS Inc., Chicago, IL, USA). p < 0.05 was considered to be significant.

Author Contributions

Conceived and designed the experiments: KL, JY CC QJ. Performed the experiments: KL ZZ JD YZ CC. Analyzed the data: KL ZZ CC QJ. Contributed reagents/materials/analysis tools: CC JD QJ. Wrote the paper: KL JY CC QJ.

References

1. Osborne NN, Casson RJ, Wood JP, Chadlow G, Graham M, et al. (2004) Retinal ischemia: mechanisms of damage and potential therapeutic strategies. Prog Retin Eye Res 23: 91–147.
2. Du ZJ, Yamamoto T, Ueda T, Suzuki M, Tano Y, et al. (2011) Activated protein C rescues the retina from ischemia-induced cell death. Invest Ophthalmol Vis Sci 52: 987–993.
3. Buettner C, Yeh GY, Phillips RS, Mittleman MA, Kaptchuk TJ (2006) Systematic review of the effects of ginseng on cardiovascular risk factors. Ann Pharmacother 40: 83–95.
4. Zhu D, Du W, Li CR, Wang XW, Ma YJ, et al. (2009) Ginsenoside Rg1 protects rat cardiomyocytes from hypoxia/reoxygenation oxidative injury via antioxidant and intracellular calcium homeostasis. J Cell Biochem 108: 117–124.
5. Vogler BK, Pinter MH, Ernst E (1999) The efficacy of ginseng. A systematic review of randomized clinical trials. Eur J Clin Pharmacol 55: 567–575.
6. Liu ZJ, Zhao M, Zhang Y, Xue JF, Chen NH (2010) Ginsenoside Rg1 promotes glutamate release via a calcium/calmodulin-dependent protein kinase II-dependent signalling pathway. Brain Res 1333: 1–8.
7. Nag SA, Qin JJ, Wang W, Wang MH, Wang H, et al. (2012) Ginsenosides as Anticancer Agents: In vitro and in vivo Activities, Structure-Activity Relationships, and Molecular Mechanisms of Action. Front Pharmacol 3: 25.
8. Huang NT, Matsumoto K, Kasa K, Yamasaki K, Watanabe H (1998) In vitro antioxidant activity of Vietnamese ginseng saponin and its components. Biol Pharm Bull 21: 578–581.
9. Liu Q, Kou JP, Yu BY (2011) Ginsenoside Rgl1 protects against hydrogen peroxide-induced cell death in PC12 cells via inhibiting NF-kappaB activation. Neurochem Int 58: 119–125.
10. Chen WF, Zhou LP, Chen L, Wu L, Gao QG, et al. (2015) Involvement of IGF-1 receptor and estrogen receptor pathways in the protective effects of ginsenoside Rgl1 against Abeta(25-35)-induced toxicity in PC12 cells. Neurochem Int 62: 1065–1071.
11. Li W, Chu Y, Zhang L, Yin L, Li L (2012) Ginsenoside Rg1 prevents SK-N-SH neuroblastoma cell apoptosis induced by supernatant from Abeta(1-40)-stimulated THP-1 monocytes. Brain Res Bull 88: 301–306.
12. Wu J, Pan Z, Wang Z, Zhu W, Shen Y, et al. (2012) Ginsenoside Rg1 protection against beta-amyloid peptide-induced neuronal apoptosis via estrogen receptor alpha and glucocorticoid receptor-dependent anti-protein nitration pathway. Neuropharmacology 63: 314–321.
13. Shen L, Han JZ, Li C, Yue SJ, Liu Y, et al. (2007) Protective effect of ginsenoside Rg1 on glutamate-induced lung injury. Acta Pharmacol Sin 28: 392–397.
14. Mu YY, Jia J, Jia Y (2012) Effects of intrathecal injection of ginsenoside Rg1 on the level of glutamate transporter in the arthritis rats with chronic morphine tolerance. Zhongguo Zhong Xi Yi Jie He Za Zhi 32: 1539-1542.
15. Xu H, Jiang H, Wang J, Xie J (2010) Rgl1 protects the MMP-9-treated MESC2.5 cells via attenuating DMT1 up-regulation and cellular iron uptake. Neuropharmacology 58: 489–494.
16. Leung KW, Yung KK, Mak NC, Chan Yas, Fan TP, et al. (2007) Neuroprotective effects of ginsenoside-Rgl1 in primary nigral neurons against rotenone toxicity. Neuropharmacology 52: 827–835.
17. Kim HJ, Kim P, Shin CY (2013) A comprehensive review of the therapeutic and pharmacological effects of ginseng and ginsenosides in central nervous system. J Ginseng Res 37: 8–29.
36. Kunz M, Ibrahim S, Koczan D, Thiesen HJ, Kohler HJ, et al. (2001) Activation of caspase-3 in mouse embryonic stem cells. Apoptosis 13: 295–304.

30. Chen Z, Shen X, Shen F, Zhong W, Wu H, et al. (2013) TAK1 activates AMPK and inhibits survival signaling pathway in murine B2 microglial cells. Curr Med Chem 19: 770–779.

35. Kim MH, Kim MO, Heo JS, Kim JS, Han HJ (2008) Acetylcholine inhibits c-Jun NH2-terminal kinase/stress-activated protein kinase (JNK/SAPK) is critical for hypoxia-induced apoptosis of human malignant melanoma. Cell Growth Differ 12: 137–145.

34. Joo SS, Won TJ, Lee DI (2005) Reciprocal activity of ginsenosides in the production of proinflammatory repertoire, and their potential roles in neuroprotection in vivo. Planta Med 71: 476–481.

33. Wu CF, Bi XL, Yang JY, Zhan JY, Dong YX, et al. (2007) Differential effects of hydrogen peroxide on NO and TNF-alpha production by LPS-activated N9 microglia. Int Immunopharmacol 7: 313–320.

32. Boulou M, Dayeh-Barker P (2001) The role of the retinal pigment epithelium, topographical variation and ageing changes. Eye (London) 15: 384–389.

31. Chen L, Xu B, Liu L, Luo Y, Yin J, et al. (2010) Hydrogen peroxide inhibits c-Jun N-terminal kinase phosphorylation in retinal Müller cells. Curr Med Chem 17: 89–93.

30. Wang WX, Wang W, Chen KJ (2005) Protective effect and mechanism of ginsenoside Rg1 on NO and TNF-alpha production by LPS-activated N9 microglia. Int Immunopharmacol 7: 313–320.

29. Brunn GJ, Williams J, Sabers C, Wiederrecht G, Lawrence JC Jr, et al. (1996) Protection of rat neonatal cardiomyocytes from ischemic injury by heat shock protein-70. Mol Cell Biochem 177: 35–44.

28. Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, et al. (2011) First-in-man clinical trial of the oral pan-PI3K inhibitor MK-2206 in patients with advanced sole tumors. J Clin Oncol 29: 4686–4695.

27. Strauss O (2005) The retinal pigment epithelium in visual function. Physiol Rev 85: 845–881.

26. Chen MB, Wu XY, Tao GQ, Liu CY, Chen J, et al. (2012) Perifosine sensitizes glioblastoma cells to doxorubicin-induced apoptosis via activation of AMPK. Biochem Biophys Res Commun 337: 1139–1144.

25. Wu CF, Bi XL, Yang JY, Zhan JY, Dong YX, et al. (2007) Differential effects of hydrogen peroxide on NO and TNF-alpha production by LPS-activated N9 microglia. Int Immunopharmacol 7: 313–320.

24. Joo SS, Won TJ, Lee DI (2005) Reciprocal activity of ginsenosides in the production of proinflammatory repertoire, and their potential roles in neuroprotection in vivo. Planta Med 71: 476–481.

23. Zong Y, Ai QL, Zhong LM, Dai JN, Yang P, et al. (2012) Ginsenoside Rg1 protects retinal pigment epithelial cells from oxidative stress and JNK pathway activation. FEBS J 280: 3708–3720.

22. Du JH, Xu N, Song Y, Xu M, Lu ZZ, et al. (2005) AICAR stimulates IL-6 production via p38 MAPK in cardiac fibroblasts in adult mice: a possible role for AMPK. Biochem Biophys Res Commun 337: 562–567.

21. Wang WX, Wang W, Chen KJ (2005) Protective effect of ginsenoside Rg1 against mitochondrial depolarization in mouse substantia nigra neurones. Acta Pharmacol Sin 26: 829–834.

20. Fang F, Chen X, Huang T, Lue LF, Luddy JS, et al. (2012) Multi-faced anti-inflammatory and anti-apoptotic effects of triterpenoids inhibit both DNA polymerase and DNA topoisomerase. J Ethnopharmacol 141: 583–591.

19. Liao B, Newmark H, Zhou R (2002) Neuroprotective effects of ginseng total polyphenol extract against hypoxia and reoxygenation. J Nutr Biochem 13: 214–226.

18. Cao C, Lu S, Kivlin R, Wallin B, Card E, et al. (2008) AMP-activated protein kinase (AMPK) activation contributes to growth inhibition of colon cancer cells. Oncol Rep 27: 562–567.

17. Kang MR, Park SK, Lee CW, Cho IJ, Jo YN, et al. (2012) Widdrol induces apoptosis via activation of AMP-activated protein kinase in colon cancer cells. Oncol Rep 27: 1407–1412.

16. Chen MB, Wu XY, Yu XY, Wu CY, Gu JH, et al. (2011) Activation of AMP-activated protein kinase is involved in vincristine-induced cell apoptosis in B16 melanoma cell. J Cell Physiol 226: 1915–1925.

15. Hayashi T, Hirshman MF, Fujii N, Mahiowski SA, Witters LA, et al. (2000) Metabolic stress and altered glucose transport: activation of AMP-activated protein kinase as a unifying coupling mechanism. Diabetes 49: 527–531.

14. Mizushima Y, Iida A, Ohita K, Sugawara F, Sakaguchi K (2000) Novel triterpenoids inhibit both DNA polymerase and DNA topoisomerase. Biochem Pharmacol 59: 757–763.

13. Tera I, Hiramoto Y, Masaki M, Sugiyma S, Kuroda T, et al. (2005) AMP-activated protein kinase protects cardiomyocytes against hypoxic injury through attenuation of endoplasmic reticulum stress. Mol Cell Biol 25: 9354–9375.

12. Mikalyeva MM, Shaw RJ (2011) The AMPK signaling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol 13: 1016–1023.

11. Inoki K, Kim J, Guan KL (2012) AMPK and mTOR in cellular energy homeostasis and drug targets. Annu Rev Pharmacol Toxicol 52: 381–400.

10. Du JH, Xu N, Song Y, Xu M, Lu ZZ, et al. (2005) AICAR stimulates IL-6 production via p38 MAPK in cardiac fibroblasts in adult mice: a possible role for AMPK. Biochem Biophys Res Commun 337: 562–567.

9. Du JH, Xu N, Song Y, Xu M, Lu ZZ, et al. (2005) AICAR stimulates IL-6 production via p38 MAPK in cardiac fibroblasts in adult mice: a possible role for AMPK. Biochem Biophys Res Commun 337: 562–567.

8. Meuse D, Van de Casteele M, Beaudeny C, Hainault I, Kefaas B, et al. (2003) Stimulation of AMP-activated protein kinase induces c-Jun-N-terminal kinase activation and apoptosis in liver cells. FEBS Lett 526: 38–42.

7. Du JH, Xu N, Song Y, Xu M, Lu ZZ, et al. (2005) AICAR stimulates IL-6 production via p38 MAPK in cardiac fibroblasts in adult mice: a possible role for AMPK. Biochem Biophys Res Commun 337: 562–567.

6. Meuse D, Van de Casteele M, Beaudeny C, Hainault I, Kefaas B, et al. (2003) Stimulation of AMP-activated protein kinase induces c-Jun-N-terminal kinase activation and apoptosis in liver cells. FEBS Lett 526: 38–42.

5. Du JH, Xu N, Song Y, Xu M, Lu ZZ, et al. (2005) AICAR stimulates IL-6 production via p38 MAPK in cardiac fibroblasts in adult mice: a possible role for AMPK. Biochem Biophys Res Commun 337: 562–567.

4. Du JH, Xu N, Song Y, Xu M, Lu ZZ, et al. (2005) AICAR stimulates IL-6 production via p38 MAPK in cardiac fibroblasts in adult mice: a possible role for AMPK. Biochem Biophys Res Commun 337: 562–567.

3. Du JH, Xu N, Song Y, Xu M, Lu ZZ, et al. (2005) AICAR stimulates IL-6 production via p38 MAPK in cardiac fibroblasts in adult mice: a possible role for AMPK. Biochem Biophys Res Commun 337: 562–567.

2. Du JH, Xu N, Song Y, Xu M, Lu ZZ, et al. (2005) AICAR stimulates IL-6 production via p38 MAPK in cardiac fibroblasts in adult mice: a possible role for AMPK. Biochem Biophys Res Commun 337: 562–567.